News & Views
Telix today reports the final results from the IPAX-1 Ph I/II study of TLX101 therapy (4-L-[ ¹³¹I] iodo-phenylalanine, or ¹³¹I-IPA) in combination with external beam radiation therapy (EBRT) in recurrent…
Read more
We are pleased to announce that Telix is supporting AdMeTech Foundation’s 6th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer, to be held virtually from September 22-24…
Read more
We are pleased to announce that Telix will be hosting a Luncheon Seminar at the 13th Congress of the World Federation of Nuclear Medicine and Biology (WFNMB), to be held at the Kyoto International Conference Center…
Read more
Telix and Nantes-based ATONCO S.A.S. (‘ATONCO’) today announced that the final patient has been dosed in a Phase I study of TLX250-CDx in patients with non-muscle invasive bladder cancer (NMIBC)…
Read more
Telix is pleased to present the Company’s financial results for the half-year ending 30 June 2022, together with a shareholder…
Read more
Telix today announces that it has been jointly awarded a $4.8 million Australian Research Council (ARC) grant to establish a new Industrial Transformation Research Program (ITRP) Hub as part of…
Read more
Telix advises that it will release financial results for the half-year ending 30 June 2022 on Thursday 18 August…
Read more
Telix today reports on regulatory progress for the Company’s core prostate and kidney cancer imaging programs in the Asia Pacific (APAC) Operating Region, including progress in the major market of…
Read more
Telix and BAMF Health use Illuccix® for the first time with uEXPLORER® total-body PET scanner for prostate cancer…
Read more
Telix issues Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 June…
Read more